
    
      A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and
      Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in
      Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or
      Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT-1)
    
  